Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a single center, retrospective trial
Our data highlight not only the significant role of the preoperative CA19-9 value and the pre- to post-chemotherapy CA19-9 ratio but, even more importantly, emphasize the critical impact of the combination of these two parameters on the resectability of BR-PDAC.
Authors
- Jürgen Weitz (ORCID: https://orcid.org/0000-0002-5760-6391)
- Felix Merboth (ORCID: https://orcid.org/0000-0003-2540-6421)
- Marius Distler (ORCID: https://orcid.org/0000-0002-3164-5755)
- Florian Oehme (ORCID: https://orcid.org/0000-0003-4997-8176)
- Lena Seifert (ORCID: https://orcid.org/0000-0003-4763-8127)
- Sebastian Hempel (ORCID: https://orcid.org/0000-0003-4268-9902)
- Christian Teske (ORCID: https://orcid.org/0000-0002-6049-4765)
- Florian Schepp
- Olga Radulova‐Mauersberger (ORCID: https://orcid.org/0000-0003-3865-095X)
- Felix von Bechtolsheim (ORCID: https://orcid.org/0000-0003-2180-7981)
- Nicolas Mibelli
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Helmholtz-Zentrum Dresden-Rossendorf (DE)
- National Center for Tumor Diseases (DE)
- University Hospital Carl Gustav Carus (DE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-19
- DOI
- https://doi.org/10.3389/fonc.2025.1602933
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00